Generic Name and Formulations:
Halobetasol propionate 0.05%; crm; oint.
Sun Pharmaceutical Industries
Indications for ULTRAVATE:
Apply a thin layer to affected areas 1–2 times daily; max 50 g/week and 2 consecutive weeks' treatment per course. Discontinue when control is achieved. Do not occlude.
Avoid use near eyes, on face, groin, or axillae. Do not use for diaper dermatitis, rosacea, perioral dermatitis, or on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, or reduce dose or potency if occurs. Treat infection if present; discontinue if infection persists or worsens. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Burning, stinging, itching, dry skin, erythema, skin atrophy, leukoderma, vesicles, rash, pustulation, acne, secondary infections, telangiectasia, urticaria, miliaria; HPA axis suppression (esp. in children).
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Prioritizing Rest in Hospital Settings: Poor Sleep Increases Costs, Complications, and Mortality
- Pain Catastrophizing Decreases in Rheumatoid Arthritis After DMARD Initiation
- Addressing Commercial Incentives in the Medical Device Industry
- Cancer Patients Treated With Step III Opioids Often Have Sleep Disturbances
- Low Literacy Self-Management Program for Chronic Pain May Be Effective